

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claims 1-16 (Canceled).

Claim 17 (Previously Presented): An immunogenic composition comprising a first antigen, a second antigen and an adjuvant, wherein: (a) the first antigen is a capsular oligosaccharide from serogroup C *N. meningitidis* (NmC) conjugated to a carrier; (b) the second antigen is proteoliposomic vesicles from serogroup B of *N. meningitidis* (NmB); and (c) the adjuvant is MF59.

Claim 18 (Previously Presented): The composition of claim 17, wherein said first antigen is conjugated to a protein carrier.

Claim 19 (Previously Presented): The composition of claim 18, wherein said protein carrier is CRM₁₉₇.

Claim 20 (Previously Presented): The composition of claim 17, wherein said NmC oligosaccharide contains 12 to about 22 repeating units from *N. meningitidis* serogroup C capsular polysaccharide.

Claim 21 (Previously Presented): The composition of claim 17, wherein said NmB is strain 44/76 (B15:P1.7, 16:L3,7,9).

Claim 22 (Previously Presented): The composition of claim 17, wherein said proteoliposomic vesicles are produced by a deoxycholate extraction process.

Claim 23 (Canceled).

Claim 24 (Currently amended): The composition of claim 17, wherein said ~~composition comprises a second carrier comprising~~ is polylactic acids acid or polyglycolic acids and the adjuvant polyglycolic acid.

Claim 25 (Previously Presented): The composition of claim 17, wherein said composition comprises immunologically effective amounts of the first and the second antigen.

Claim 26 (Previously Presented): An immunogenic composition comprising an immunologically effective amount of a first antigen and an immunologically effective amount of a second antigen, wherein: (a) the first antigen is a capsular oligosaccharide from serogroup C *N. meningitidis* (NmC), conjugated to CRM₁₉₇, and contains from 12 to 22 repeating units from the NmC capsular polysaccharide and (b) the second antigen is proteoliposomic vesicles from strain 44/76 (B15:P1.7, 16:L3,7,9) of serogroup B *N. meningitidis* (NmB), wherein said proteoliposomic vesicles are produced by a deoxycholate extraction process.

Claim 27 (Previously Presented): The composition of claim 26, wherein said composition further comprises aluminum hydroxide or MF59.

Claim 28 (Currently amended): The composition of claim 26, wherein said composition further comprises a ~~second carrier, wherein said carrier comprising polylactic acids or polyglycolic acids~~ is polylactic acid or polyglycolic acid.

Claim 29 (Withdrawn): A method of inducing an immunologic response to NmB and NmC in a mammalian subject, comprising administering an immunologically effective amount of an immunogenic composition of any of claims 17-28 to said mammalian subject.

Claim 30 (Previously Presented): An immunogenic composition comprising a first antigen, a second antigen and an adjuvant, wherein: (a) the first antigen is a capsular oligosaccharide from serogroup C *N. meningitidis* containing 12 to about 22 repeating units from *N. meningitidis* serogroup C capsular polysaccharide conjugated to a carrier, and (b) the second antigen is proteoliposomic vesicles from serogroup B of *N. meningitidis* (NmB).